Accelerating Our Journey of Innovation and Growth!

Since its launch in 2021, VARIXIO has enjoyed strong and steady growth, being now present in over 750 clinics, in more than 30 countries. This success underscores our commitment to advancing foam sclerotherapy as a transformative treatment for varicose veins.

Building on this progress, we are looking forward to entering new markets and bringing continued innovation to our product line.

To fuel this next stage of development, we are planning a new funding round and are eager to connect with investors who share our passion for enhancing care and improving outcomes in venous disease.

We’re grateful for the support of our clients and partners in making our success possible. Together, we are driving innovation in vein treatment!

Be a part of our journey!

Invest with us through Capital Cell

Building on this progress, we are excited to announce that our new funding round is now officially open! We invite everyone who share our passion for enhancing care and improving outcomes in venous disease to join us.

Capital Cell is an international life science investment platform. Find all the details regarding the investment round, about Capital Cell and including on how to invest:

Invest in VB Devices Now

Contact Form

If you have any further questions regarding the investment or need additional details, please complete the form below. 

Don’t hesitate to contact us if you have any further questions: info@vbdevices.com

By providing your personal data in this form, you consent to its processing in accordance with our Privacy Policy. The information you provide will be used exclusively to respond to your inquiry and to inform you about our upcoming funding round. We are committed to protecting your privacy and ensuring the security of your data. We will not share your personal information with third parties without your consent, except as required by law. You may request to access, update, or delete your data at any time by contacting us at [contact email]. For more details, please refer to our Privacy Policy.